Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure

Inclusion Criteria:

• Adults of both sexes, regardless of color or social class

• Age over 18 years with a good clinical medical criteria

• Patients who agreed to participate and signed the Informed Consent

• Insufficient patients in chronic renal dialysis schedule (3 times per week)

• Patients with creatinine clearance <30ml/min

• Patients with indication for anticoagulation during hemodialysis

Exclusion Criteria:

• Patients with sensitivity to heparin sodium;

• Patients with hypersensitivity to benzyl alcohol

• Patients with a history of bleeding or illness that can change the blood coagulationaggravate or terminate the clinical picture, such as tables of gastric ulcer

• Patients with a history of peptic ulcer

• Patients with body mass index greater than 30

• Cancer patients because of the possibility of compromising the function of thevariable coagulation

• Patients in period of pregnancy or after delivery

• Patients with genetic abnormality of the clotting system

• Polytraumatized patients

• Patients using glucocorticoids for at least 1 month

• Patients using other anticoagulants

• Patients with high rate of bleeding

• Patients undergoing any surgery performed less than 15 days due to the risk oftraining of hematoma at the site of surgery

• Hypertension above 140/90 mmHg

• Patients using medications that could affect hemostasis

• Patients using the following medicines: hormonal anti not including Ketorolac; Dextran 40, ticlopidine and clopidogrel, systemic glucocorticoids, thrombolytic agents andanticoagulants and other antiplatelet agents, including antagonists of glycoproteinIIb / IIIa.